Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

T-cell abnormalities in common variable immunodeficiency

J S Jaffe1, E Eisenstein, M C Sneller

  • 1Mucosal Immunity Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892.

Pediatric Research
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Agreement and disagreement in pediatric functional neurological symptom disorders: Comparing patient reported outcome measures (PROMs) and clinician assessments.

Computational and structural biotechnology journal·2024
Same author

Immunopathogenesis of pancreatitis.

Mucosal immunology·2016
Same author

Decline of cellular activation in non-B cells after rituximab treatment in hepatitis C-associated mixed cryoglobulinemia vasculitis.

Journal of viral hepatitis·2016
Same author

Nucleotide-binding oligomerization domain 1 acts in concert with the cholecystokinin receptor agonist, cerulein, to induce IL-33-dependent chronic pancreatitis.

Mucosal immunology·2016
Same author

The regulation of gastrointestinal immune responses.

Immunology today·2014
Same author

NOD2 downregulates colonic inflammation by IRF4-mediated inhibition of K63-linked polyubiquitination of RICK and TRAF6.

Mucosal immunology·2014
Same journal

Polycyclic aromatic hydrocarbons and perinatal outcomes: a scoping review.

Pediatric research·2026
Same journal

Interindividual variability in metformin pharmacokinetics in pediatric patients.

Pediatric research·2026
Same journal

Comparison of Crohn's disease exclusion diet and exclusive enteral nutrition in prospectively followed paediatric patients with Crohn's disease.

Pediatric research·2026
Same journal

Natural Language Processing (NLP) tools are superior to ICD-10 codes in capturing clinically relevant information.

Pediatric research·2026
Same journal

Prenatal cannabinoid and nicotine exposure: senescence as a developmental origin of bronchopulmonary dysplasia?

Pediatric research·2026
Same journal

Bob Sun: ECI Biocommentary.

Pediatric research·2026
See all related articles

Common variable immunodeficiency (CVI) involves distinct immune defects. Some CVI patients show T-cell defects in lymphokine production, while others have altered T-cell subsets that can suppress B-cell function.

Area of Science:

  • Immunology
  • Molecular Biology
  • Cell Biology

Background:

  • Common variable immunodeficiency (CVI) is a complex disorder with diverse immunological abnormalities.
  • Understanding the specific cellular and molecular defects in CVI is crucial for diagnosis and treatment.

Purpose of the Study:

  • To investigate the detailed immunologic defects in different patient groups within CVI.
  • To characterize T-cell lymphokine production and identify specific cellular abnormalities in CVI.

Main Methods:

  • Stimulation of T-cells with various activation stimuli, including phytohemagglutinin and CD3-T-cell receptor complex activation.
  • Analysis of lymphokine (IL-2, IL-4, IL-5, interferon-gamma) mRNA and protein production.
  • Flow cytometry to assess T-cell subsets (CD4/CD8 ratio, CD57 marker).

Related Experiment Videos

  • Functional assays to evaluate T-cell suppression of B-cell immunoglobulin production.

    • Main Results:

    • One CVI subgroup (approx. 60%) exhibits T-cells with reduced IL-2, IL-4, and IL-5 production, but normal interferon-gamma when IL-2 is present, suggesting a downstream defect in lymphokine gene activation.
    • A second CVI subgroup (approx. 30%) presents with a reduced CD4/CD8 ratio and increased CD57+ CD8+ T-cells.
    • In the second subgroup, CD8+ T-cells produce increased interferon-gamma and exhibit suppressor activity on IgG production by B-cells.

    Conclusions:

    • CVI is characterized by at least two distinct T-cell related immunologic defects.
    • The findings highlight the heterogeneity of CVI and point to specific molecular and cellular pathways that are impaired.
    • Further research into these defects may lead to targeted therapies for CVI patients.